<table-wrap xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink" id="table2" position="float"><object-id pub-id-type="doi">10.7554/eLife.27402.026</object-id><label>Table 2.</label><caption><title>Primary antibodies used for IF staining and/or western-blotting.</title></caption><table frame="hsides" rules="groups"><thead><tr><th>Primary antibody</th><th>Company</th></tr></thead><tbody><tr><td>anti-BCAS2</td><td>Abcam, Cambridge, UK (RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1861326">AB_1861326</ext-link>)</td></tr><tr><td>anti-CDC5L</td><td>BD Transduction Laboratories <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_399724">AB_399724</ext-link>)</td></tr><tr><td>anti-coilin</td><td>Proteintech, Chicago, IL, US <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2276345">AB_2276345</ext-link>)</td></tr><tr><td>anti-CSTF2</td><td>Santa Cruz, US <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_668179">AB_668179</ext-link>)</td></tr><tr><td>anti-CTNNBL1</td><td>Abcam, Cambridge, UK <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1523420">AB_1523420</ext-link>)</td></tr><tr><td>anti-DDX46</td><td>Proteintech, Chicago, IL, US <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2090927">AB_2090927</ext-link>)</td></tr><tr><td>anti-Fibrillarin</td><td>Cytoskeleton Inc, Denver, CO, US <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10709399">AB_10709399</ext-link>)</td></tr><tr><td>anti-PRPF40A</td><td>Novus, Biologicals, Chambridge, UK <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11012473">AB_11012473</ext-link>)</td></tr><tr><td>anti-PLRG1</td><td>Abcam, Cambridge, UK <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2170868">AB_2170868</ext-link>)</td></tr><tr><td>anti-PRP19</td><td>Abcam, Cambridge, UK <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2170868">AB_2170868</ext-link>)</td></tr><tr><td>anti-NEDD8</td><td>Cell Signaling Technology, Danvers, MA, US <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_659972">AB_659972</ext-link>)</td></tr><tr><td>anti-SF3B1</td><td>Abcam, Cambridge, UK <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2186512">AB_2186512</ext-link>)</td></tr><tr><td>anti-SF3B2</td><td>Novus Biologicals, Abington, UK <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_1110397">AB_1110397</ext-link>)</td></tr><tr><td>anti-SFRS1</td><td>Abcam, Cambridge, UK <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_298608">AB_298608</ext-link>)</td></tr><tr><td>anti-SMN</td><td>ImmunoGlobe, Himmelstadt, Germany <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2687973">AB_2687973</ext-link>)</td></tr><tr><td>anti-SNRPA1</td><td>Abcam, Cambridge, UK <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_11139816">AB_11139816</ext-link>)</td></tr><tr><td>anti-snRNP200</td><td>Abcam, Cambridge, UK <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10901078">AB_10901078</ext-link>)</td></tr><tr><td>anti-SR proteins</td><td>Merck Group, Darmstadt, Germany <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10807429">AB_10807429</ext-link>)</td></tr><tr><td>anti-SUMO1</td><td>Cell Signaling Technology, Danvers, US <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_10698887">AB_10698887</ext-link>)</td></tr><tr><td>anti-SUMO2/3</td><td>Cell Signaling Technology, Danvers, US <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2198425">AB_2198425</ext-link>)</td></tr><tr><td>anti-TMG</td><td>Merck Group, Darmstadt, Germany <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2687977">AB_2687977</ext-link>)</td></tr><tr><td>anti-U1A</td><td>Iain Mattaj <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2713922">AB_2713922</ext-link>)</td></tr><tr><td>anti-U2AF65</td><td>SIGMA, ST Louis, Missouri, US <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_262122">AB_262122</ext-link>)</td></tr><tr><td>anti-Ubiquitin</td><td>Cell Signaling Technology, Danvers, US <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2180538">AB_2180538</ext-link>)</td></tr><tr><td>anti-Y12</td><td>Joan Steitz <break/>(RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/AB_2692320">AB_2692320</ext-link>)</td></tr></tbody></table></table-wrap>